PMID- 37806440
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231114
IS  - 1098-8823 (Print)
IS  - 1098-8823 (Linking)
VI  - 169
DP  - 2023 Dec
TI  - Effect of specialized pro-resolving lipid mediators in the regulation of vascular 
      tone and inflammation in human saphenous vein.
PG  - 106786
LID - S1098-8823(23)00083-7 [pii]
LID - 10.1016/j.prostaglandins.2023.106786 [doi]
AB  - Specialized pro-resolving lipid mediators (SPMs), derived from polyunsaturated 
      fatty acids are important mediators in the resolution of inflammation. Recent 
      studies have focused on the effects of SPMs in cardiovascular health and 
      diseases. However, little is known about the effect SPMs on human vascular tone. 
      Therefore, in this study it is aimed to investigate the effect of various SPMs 
      including resolvin D- and E-series, maresin-1 (MaR1) and lipoxin-A4 (LxA4) on the 
      vascular tone of human isolated saphenous vein (SV) preparations under 
      inflammatory conditions. In addition, we aimed to evaluate the effects of SPMs on 
      the release of pro-inflammatory mediators, monocyte chemoattractant protein-1 
      (MCP-1) and tumor necrosis factor-alpha (TNF- alpha) from human SV. Pretreatment of 
      isolated of human SV with resolvin E1 (RvE1), resolvin D1 (RvD1) and MaR1 
      (100 nM, 18 h) significantly reduced the contractile responses to thromboxane A2 
      mimetic, U46619 whereas pretreatment with LxA4 and RvD2 (100 nM, 18 h) had no 
      significant effect on the vascular tone of SV. Moreover, RvE1, RvD1 and MaR1 but 
      not LxA4 and RvD2 (100 nM, 18 h) pretreatment diminished the release of MCP-1 and 
      TNF-alpha from SV. In conclusion, our findings suggest that pre-treatment with RvE1, 
      RvD1, and MaR1 could have potential benefits in decreasing graft vasospasm and 
      vascular inflammation in SV.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Celik, Zeynep
AU  - Celik Z
AD  - Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, 
      Turkey; Department of Pharmacology, Istanbul University, Institute of Graduate 
      Studies in Health Sciences, Istanbul, Turkey.
FAU - Ozen, Gulsev
AU  - Ozen G
AD  - Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, 
      Turkey.
FAU - Sunar, Seynur
AU  - Sunar S
AD  - Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, 
      Turkey; Department of Pharmacology, Istanbul University, Institute of Graduate 
      Studies in Health Sciences, Istanbul, Turkey.
FAU - Turkyilmaz, Saygin
AU  - Turkyilmaz S
AD  - Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk Education and 
      Research Hospital Bakirkoy, Istanbul, Turkey.
FAU - Turkyilmaz, Gulsum
AU  - Turkyilmaz G
AD  - Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk Education and 
      Research Hospital Bakirkoy, Istanbul, Turkey.
FAU - Kavala, Ali Aycan
AU  - Kavala AA
AD  - Department of Cardiovascular Surgery, Bakirkoy Dr. Sadi Konuk Education and 
      Research Hospital Bakirkoy, Istanbul, Turkey.
FAU - Teskin, Onder
AU  - Teskin O
AD  - Department of Cardiovascular Surgery, Biruni University, Istanbul, Turkey.
FAU - Dogan, B Sonmez Uydes
AU  - Dogan BSU
AD  - Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, 
      Turkey.
FAU - Topal, Gokce
AU  - Topal G
AD  - Department of Pharmacology, Istanbul University Faculty of Pharmacy, Istanbul, 
      Turkey. Electronic address: gtopal@istanbul.edu.tr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231006
PL  - United States
TA  - Prostaglandins Other Lipid Mediat
JT  - Prostaglandins & other lipid mediators
JID - 9808648
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Inflammation Mediators)
SB  - IM
MH  - Humans
MH  - *Saphenous Vein
MH  - *Docosahexaenoic Acids/pharmacology
MH  - Inflammation
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
MH  - Chemokine CCL2
MH  - Inflammation Mediators
OTO - NOTNLM
OT  - Human saphenous vein
OT  - Omega polyunsaturated fatty acids
OT  - Specialized pro-resolving lipid mediators
OT  - Vascular inflammation
OT  - Vascular tone
COIS- Conflicts of Interest The authors declare no conflict of interest.
EDAT- 2023/10/09 00:42
MHDA- 2023/11/13 06:42
CRDT- 2023/10/08 19:27
PHST- 2023/04/13 00:00 [received]
PHST- 2023/09/23 00:00 [revised]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2023/11/13 06:42 [medline]
PHST- 2023/10/09 00:42 [pubmed]
PHST- 2023/10/08 19:27 [entrez]
AID - S1098-8823(23)00083-7 [pii]
AID - 10.1016/j.prostaglandins.2023.106786 [doi]
PST - ppublish
SO  - Prostaglandins Other Lipid Mediat. 2023 Dec;169:106786. doi: 
      10.1016/j.prostaglandins.2023.106786. Epub 2023 Oct 6.